Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.

Autor: Ebenig A; Division of Veterinary Medicine, Paul-Ehrlich-Institut, D-63225, Langen, Germany., Lange MV; Division of Veterinary Medicine, Paul-Ehrlich-Institut, D-63225, Langen, Germany., Mühlebach MD; Division of Veterinary Medicine, Paul-Ehrlich-Institut, D-63225, Langen, Germany. Michael.Muehlebach@pei.de.
Jazyk: angličtina
Zdroj: NPJ vaccines [NPJ Vaccines] 2022 Oct 15; Vol. 7 (1), pp. 119. Date of Electronic Publication: 2022 Oct 15.
DOI: 10.1038/s41541-022-00543-4
Abstrakt: Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: